GlobeNewsWire
11 Aug 2026, 21:53 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
ARS Pharmaceuticals failed to secure expanded insurance coverage for its epinephrine nasal spray, neffy, through CVS Caremark by the July 1, 2026 deadline. — Lack of insurance coverage during peak seasonal demand (summer/back-to-school) directly limits revenue potential and market penetration for a core product.
-0.80A class action lawsuit has been filed against ARS Pharmaceuticals alleging securities fraud or other unlawful business practices. — Legal challenges regarding corporate conduct create uncertainty and potential financial liabilities for the company.
-0.50CVS Caremark has deferred its decision on expanded insurance coverage for neffy until January 2027. — This creates a prolonged period of commercial uncertainty regarding the product's reimbursement status.
-0.30Which stocks this story touches
Continue reading
6 related stories
Top 2 movers · tap to explore
The company is facing a class action lawsuit alleging securities fraud following a significant stock price drop and insurance coverage failure.
The company is being investigated for claims on behalf of investors by a law firm.
A class action lawsuit has been filed against the company.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
GlobeNewsWire
1h ago
